NYSE:MDTMedical Equipment
How Investors Are Reacting To Medtronic (MDT) Balancing Growth, Margin Pressure, And A Diabetes Spin-Off
In February 2026, Medtronic plc reported third-quarter fiscal 2026 results showing higher sales of US$9,017 million but lower net income of US$1,143 million year-on-year, reaffirmed full-year EPS guidance of US$5.62 to US$5.66, and received U.S. FDA clearance for its Stealth AXiS spine surgical system.
These updates, alongside a US$381 million antitrust jury verdict against Medtronic and ongoing diabetes-business restructuring, highlight a company balancing innovation and legal, margin, and...